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The unwavering commitment of regulatory T cells in
the suppression of autoimmune encephalomyelitis:
Another aspect of immune privilege in the CNS
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FoxP3+ regulatory T (Treg) cells accumulate in the central nervous system (CNS) during
experimental autoimmune encephalomyelitis and have been shown to limit the extent of
neuroinflammation and to facilitate clinical recovery. The recent demonstration that Treg
cells lose FoxP3 expression and assume effector cell characteristics upon stimulationwith
proinflammatory cytokines has raised questions about their stability in the inflamed CNS.
In this issue of the European Journal of Immunology, O’Connor et al. [Eur. J. Immunol.
2012. 42: 1164–1173] show that CNS-infiltrating Treg cells maintain their suppressor
phenotype by downregulating the IL-6 receptor. This commentary discusses the finding
particularly with relevance to therapy of multiple sclerosis.
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The central nervous system (CNS) microenvironment is not con-
ducive to the generation of immune responses, a characteristic
that is likely the consequence of evolutionary adaptation. The
brain and spinal cord are especially vulnerable to collateral dam-
age from inflammatory insults due to the poor regenerative capac-
ities of neurons and axons. This is illustrated by the pathological
landmarks of multiple sclerosis (MS), in which progressive neu-
rodegeneration is driven by perivascular inflammatory infiltrates
[1,2]. The immune privileged status of the CNS is based, in large
part, on the lack of an “infrastructure” to support lymphocyte re-
cruitment and activation. Hence, it is one of the few tissues bereft
of lymphatic vessels. Cerebrovascular endothelial cells express rel-
atively low levels of adhesion molecules and resident myeloid cells
express low levels of MHC class II and costimulatory molecules
during homeostasis [3]. In the current issue of the European Jour-
nal of Immunology, O’Connor et al. [4] demonstrate that the CNS
microenvironment also dampens inflammation by bolstering the
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stability of infiltrating FoxP3+ CD4+ regulatory T (Treg) cells.
Specifically, they found that Treg cells isolated from the CNS, but
not from peripheral lymphoid tissues, of mice with experimen-
tal autoimmune encephalomyelitis (EAE), retain their suppressor
phenotype and resist conversion to IL-17-producing cells in re-
sponse to the proinflammatory cytokine IL-6.
FoxP3+CD25+CD4+ Treg cells accumulate in the brain and
spinal cord during EAE, reaching their highest frequency coinci-
dent with clinical remission [5]. Several groups have found that
Treg cells isolated from the inflamed CNS are more potent sup-
pressors of conventional T-cell proliferation than Treg cells iso-
lated from peripheral lymphoid tissues [6,7]. The role of Treg
cells in modulating encephalitogenic T cells in vivo was first sug-
gested by the observation that mice expressing a transgenic myelin
protein-reactive T-cell receptor succumbed to spontaneous EAE
when backcrossed to a T-cell deficient background [7]. It was
subsequently shown that resistance of these mice to autoimmune
demyelination is restored by reconstitution with CD25+CD4+ Treg
cells [8,9]. Consistent with these findings, the adoptive transfer of
Treg cells (either isolated from the CNS of mice that had recovered
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from EAE, or generated in vitro by the stimulation of na¨ıve CD25-
CD4+ T cells with IL-2 and TGF-β), reduces the incidence and
severity of EAE in wild-type mice [5,10]. Conversely, depletion of
Treg cells enhances disease severity and impedes clinical recov-
ery [5,11]. Treg cells from individuals with MS have been found
to be relatively inefficient in in vitro suppression assays [12,13].
Together, these data demonstrate that FoxP3+CD25+CD4+ Treg
cells can limit the extent and duration of neuroinflammation. How-
ever, their mechanism and site of action in that capacity are poorly
understood.
Based on the preferential accumulation of adoptively trans-
ferred CD4+CD25+ donor T cells in the lymphoid tissues of mice
with EAE shown in their study, Kohm et al. [14] speculated that
Treg cells exert their protective functions in the periphery. In sup-
port of this notion, recent insights regarding the plasticity of Treg
cells suggest that their suppressive functions could be undermined
in the inflamed CNS. Hence, multiple laboratories have indepen-
dently demonstrated that Treg cells downregulate FoxP3 and up-
regulate IL-17 (as well as other Th17 cell-associated molecules,
including IL-17F, RORγt, and IL-23 receptor) following activation
in the presence of proinflammatory cytokines that are expressed in
the CNS during EAE, such as IL-6, IL-1β, and IL-23 [15–1815-18].
Among these factors, IL-6 has been most prominently implicated
[17,18].
IL-6 is expressed in acute and chronic active plaques in the
brains of patients with MS and animals with EAE, where it is as-
sociated with resident glial cells [19,20]. Treg cells have been
shown to catalyze their own transformation into IL-17 producers,
as well as to promote the Th17-cell differentiation of uncommit-
ted “bystander” T cells, by acting as a source of TGF-β in an IL-6
rich environment [18]. Treg cells that have transitioned into IL-
17 producers (so called “exTreg” cells) are compromised in their
ability to inhibit the activation of conventional T cells in vitro and
to suppress inflammatory events in vivo [15,17]. These observa-
tions beg the question as to whether autoreactive exTreg cells can
mediate destructive inflammation within a target organ, commen-
surate with their Th effector counterparts. Indeed, exTreg cells
specific for a pancreatic islet autoantigen induce diabetes follow-
ing transfer in lymphopenic hosts [16,21]. However, a paradoxical
disease-inciting role of Treg cells in EAE is belied by the fact that
in vivo depletion of CD25+ T cells or a genetic deficiency of Treg
cells exacerbates, rather than suppresses, clinical signs [5,7,9,11].
This suggests that endogenous Treg cells are actively stabilized in
the CNS during EAE, in spite of the presence of proinflammatory
cytokines. O’Connor et al. [4] now report that such Treg-cell stabi-
lization is achieved via downregulation of both chains of the IL-6
receptor (IL-6R), CD126 and gp130. It is interesting that FoxP3
negative T cells, as well as Treg cells, were found to be IL-6R
negative in the CNS of mice with EAE. The downregulation of
IL-6R on uncommitted conventional T cells could provide an ad-
ditional layer of protection against EAE relapse or progression, by
preempting the emergence of Th17 effectors reactive against sec-
ondary myelin epitopes in the context of epitope spreading [22].
The plasticity of Treg cells is determined, in part, by their on-
togeny. Most recently, it was reported that the majority of ex-
FoxP3 cells are derived from a minor population of conventional
T cells that transiently upregulate FoxP3 but that never fully com-
mit to a regulatory lineage (as reflected by a lack of suppres-
sor function and the presence of a methylated Treg cell-specific
demethylation region, or TSDR) [23]. In the current article, bisul-
fite sequence analysis of CNS-infiltrating FoxP3+ cells revealed
complete demethylation of the TSDR, making it unlikely that they
represent conventional T cells with promiscuous FoxP3 expres-
sion. In fact, the demethylated status of the TSDR in CNS Treg
cells is most reminiscent of the thymically derived “natural” Treg
(nTreg) cell subset. It has been claimed that nTreg cells are more
susceptible to IL-6-mediated Th17 deviation than peripherally de-
rived, “inducible” Treg (iTreg) cells [16,17]. Collectively, these
data suggest that the insensitivity of CNS nTreg cells to IL-6 is
imperative for their stability during EAE. Since IL-12, IL-23, and
IFNγ can stimulate Treg cells to acquire effector cell character-
istics [15,16,24], it would be instructive to determine whether
expression of each of their receptors is also reduced on CNS Treg
cells.
A number of important questions have yet to be answered. For
example, are Treg cells triggered to downregulate IL-6R after they
enter the brain and spinal cord? If so, what are the factors in the
brain and spinal cord that suppress IL-6R expression? IL-10 merits
consideration as a candidate Treg-cell stabilizing factor because it
is upregulated in the CNS during EAE remissions and because IL-
10 deficiency or neutralization delays clinical recovery [5,25]. Al-
ternatively, are IL-6R expressing Treg cells selectively recruited to
the CNS from the periphery or do they have a survival/proliferative
advantage over other Treg-cell subsets within the CNS microen-
vironment? The majority of Treg cells isolated from the CNS of
mice with EAE express CXCR3, a chemokine receptor that has
been implicated in CNS homing of effector T cells and in Treg
cell migration to sites of inflammation [24]. CXCR3+ Treg cells
isolated from the spleen of the same mice tended to be IL-6R posi-
tive. Hence, peripheral Treg cells that migrate to the brain during
the course of EAE are likely enriched with IL-6R expressing cells.
In experimental models of gliomas, the CCR4/CCL22-CCL2 axis
drives Treg cell recruitment to the brain [26]. The importance of
CCR4 expression for Treg cell trafficking in mice with EAE, and the
relationship between CCR4 and IL-6R expression on Treg, remain
to be elucidated.
Irrespective of the answers to the above questions, the findings
of O’Conner et al. [4] hold important implications for the treat-
ment of MS. As the authors themselves discuss, concerns over the
therapeutic administration of Treg cells (and, in particular, au-
toreactive Treg cells) based on their potential for transformation
into pathogenic effectors, might be defused if it were established
that the CNS provides a stabilizing environment. That statement
is made with the caveats that: (i) the behavior of endogenous
Treg cells with a demethylated TSDR might not reflect the behav-
ior of Treg cells that are induced from FoxP3- precursors and/or
that are artificially expanded in vitro for therapeutic purposes,
and (ii) if donor Treg cells are administered systemically, Th17-
cell deviation could occur in the more permissive lymphoid tis-
sues. The current study [4] highlights the potential efficacy of IL-6
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neutralization or IL-6 receptor blockade as therapeutic interven-
tions in MS. In addition to thwarting the development of encephal-
itogenic Th17 cells [19], IL-6/IL-6R targeting agents could aug-
ment the immunosuppressive activities of Treg cells at the very
site of neuroinflammation. An issue of wide-ranging therapeutic
significance concerns the universality of the phenomena reported
by O’Connor et al. [4]. Hence, are pathways that reinforce Treg
cell properties unique to the immune-privileged CNS, or do they
also exist in other body compartments? If the latter is the case,
then stabilization of Treg cells via downregulation of IL-6R could
contribute to the restraint and resolution of a spectrum of organ-
specific autoimmune diseases.
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